Milberg Weiss Announces the Filing of a Class Action Suit against TASER International, Inc. and Certain of Its Officers and Directors on Behalf of Investors.

NEW YORK -- The law firm of Milberg Weiss Bershad & Schulman LLP announces that a class action lawsuit was filed on January 19, 2005, on behalf of purchasers of the securities of TASER International, Inc. ("TASER" or the "Company") (Nasdaq: TASR) between October 18, 2004 and January 6, 2005, inclusive (the "Class Period") seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act").

The action is pending in the United States District Court for the District of Arizona against defendants TASER, Patrick W. Smith (CEO), Thomas P. Smith (President), Philip W. Smith (director). A copy of the complaint filed in this action is available from the Court, or can be viewed on Milberg Weiss's website at: http://www.milbergweiss.com

The Complaint alleges that, throughout the Class Period, TASER has aggressively fostered the perception that its products are non-lethal, generally safe and, therefore, ideal for temporarily incapacitating suspects without killing them or causing permanent injuries. This perception was crucial to the marketability of TASER products and the success of the Company. When this perception was challenged, as it repeatedly was during the Class Period, the Company aggressively defended it. On October 18, 2004, defendants issued a press release announcing that a U.S. Department of Defense study by the Human Effects Center of Excellence ("HECOE") "conclude(ed) that TASER technology is generally effective without significant risk of unintended results." In the press release, defendant Patrick Smith touted the study as the "latest chapter in a series of comprehensive medical and scientific studies which conclude that TASER technology is safe and effective." During the week following defendants' announcement affirming the safety of the Company's products, TASER insiders, including the Individual Defendants, sold a total of $67 million worth of TASER stock. During the Class Period, TASER insiders, including the individual defendants, sold a total of 3,317,212 shares of TASER common stock for gross proceeds of $96,261,155. The Company's characterization of the HECOE study, and other Class Period statements particularized in the Complaint, was materially false and misleading because, in marked contrast to the Company's unequivocally positive characterization of the study's conclusions, the study in fact found that TASER technology could be dangerous and that more information was needed to evaluate its risks.

On January 6, 2004, after the close of ordinary trading, TASER issued a press release announcing that the SEC had commenced an inquiry into the Company's statements concerning the safety of its products. In addition, the SEC sought information concerning a suspicious, large end-of-quarter (4Q) sale to one of the Company's distributors. In reaction to this announcement, the price of TASER common stock plummeted, falling from $27.62 per share on January 6, 2005, to $21.29 per share on January 7, 2005, a one-day drop of 23% on unusually heavy trading volume of over 35 million shares.

If you bought the securities of TASER between October 18, 2004 and January 6, 2005, and sustained damages, you may, no later than March 11, 2005, request that the Court appoint you as lead plaintiff. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Milberg Weiss Bershad & Schulman LLP, or other counsel of your choice, to serve as your counsel in this action.

Milberg Weiss Bershad & Schulman LLP (http://www.milbergweiss.com) is a firm with over 100 lawyers with offices in New York City, Los Angeles, Boca Raton, Delaware, Seattle and Washington, D.C. and is active in major litigations pending in federal and state courts throughout the United States. Milberg Weiss has taken a leading role in many important actions on behalf of defrauded investors, consumers, and others for nearly 40 years. Please contact the Milberg Weiss website for more information about the firm. If you wish to discuss this action with us, or have any questions concerning this notice or your rights and interests with regard to the case, please contact the following attorneys:

Steven G. Schulman
Peter E. Seidman
Andrei V. Rado
One Pennsylvania Plaza, 49th fl.
New York, NY, 10119-0165
Phone number: [phone]
Email: [e-mail]
Website: http://www.milbergweiss.com